Journal of Antimicrobial Chemotherapy, Vol 42, 703-709, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
FJ Boswell, JM Andrews, JP Ashby, C Fogarty, NP Brenwald and R Wise
The in-vitro activity of HMR 3647, a novel ketolide, was investigated in
comparison with those of erythromycin A, roxithromycin, clarithromycin
(14-membered ring macrolides), amoxycillin-clavulanate and ciprofloxacin
against 719 recent clinical Gram-positive, Gram- negative and anaerobic
isolates and type cultures. HMR 3647 generally demonstrated greater
activity than the other compounds with MIC90s of < or =0.5 mg/L, except
for Staphylococcus epidermidis (MIC90 > 128 mg/L), Haemophilus
influenzae (MIC90 = 2 mg/L), Enterococcus faecalis (MIC90 = 2 mg/L),
Enterococcus faecium (MIC90 = 1 mg/L) and the anaerobes, Bacteroides
fragilis (MIC90 = 2 mg/L) and Clostridium difficile (MIC90 = 1 mg/L). In
general, an increase in the size of the inoculum from 10(4) to 10(6) cfu on
selected strains had little effect on the MICs of HMR 3647. Additionally,
the in-vitro activity of HMR 3647 was not affected by the presence of
either 20 or 70% (v/v) human serum. The antichlamydial activity of HMR 3647
was generally greater than that of commonly used antichlamydial
antimicrobials.
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent [In Process Citation]
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. T. Labro, H. Abdelghaffar, and C. Babin-Chevaye Interaction of the New Ketolide ABT-773 (Cethromycin) with Human Polymorphonuclear Neutrophils and the Phagocytic Cell Line PLB-985 In Vitro Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1096 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. John, C. Pletch, and Z. Hussain In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci J. Antimicrob. Chemother., December 1, 2002; 50(6): 933 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Liu and S. Douthwaite Activity of the Ketolide Telithromycin Is Refractory to Erm Monomethylation of Bacterial rRNA Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1629 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Abdelghaffar, D. Vazifeh, and M. T. Labro Cellular Uptake of Two Fluoroketolides, HMR 3562 and HMR 3787, by Human Polymorphonuclear Neutrophils In Vitro Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2798 - 2806. [Abstract] [Full Text]
|
|
|
|
|
|
N. Miyashita, H. Fukano, Y. Niki, and T. Matsushima In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae J. Antimicrob. Chemother., September 1, 2001; 48(3): 403 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-I. Morosini, R. Canton, E. Loza, M.-C. Negri, J.-C. Galan, F. Almaraz, and F. Baquero In Vitro Activity of Telithromycin against Spanish Streptococcus pneumoniae Isolates with Characterized Macrolide Resistance Mechanisms Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2427 - 2431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bonnefoy, M. Guitton, C. Delachaume, P. Le Priol, and A.-M. Girard In Vivo Efficacy of the New Ketolide Telithromycin (HMR 3647) in Murine Infection Models Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1688 - 1692. [Abstract] [Full Text]
|
|
|
|
|
|
A. Bonnefoy and P. Le Priol Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics J. Antimicrob. Chemother., April 1, 2001; 47(4): 471 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jalava, J. Kataja, H. Seppälä, and P. Huovinen In Vitro Activities of the Novel Ketolide Telithromycin (HMR 3647) against Erythromycin-Resistant Streptococcus Species Antimicrob. Agents Chemother., March 1, 2001; 45(3): 789 - 793. [Abstract] [Full Text]
|
|
|
|
|
|
B. Vester and S. Douthwaite Macrolide Resistance Conferred by Base Substitutions in 23S rRNA Antimicrob. Agents Chemother., January 1, 2001; 45(1): 1 - 12. [Full Text]
|
|
|
|
|
|
I. Odenholt, E. Löwdin, and O. Cars Pharmacodynamics of Telithromycin In Vitro against Respiratory Tract Pathogens Antimicrob. Agents Chemother., January 1, 2001; 45(1): 23 - 29. [Abstract] [Full Text]
|
|
|
|
|
|
L. Piroth, N. Desbiolles, V. Mateo-Ponce, L. Martin, C. Lequeu, P.-E. Charles, H. Portier, and P. Chavanet HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., January 1, 2001; 47(1): 33 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Namour, D. H. Wessels, M. H. Pascual, D. Reynolds, E. Sultan, and B. Lenfant Pharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple Doses Antimicrob. Agents Chemother., January 1, 2001; 45(1): 170 - 175. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Andrews, T. M. A. Weller, J. P. Ashby, R. M. Walker, and R. Wise The in vitro activity of ABT773, a new ketolide antimicrobial agent J. Antimicrob. Chemother., December 1, 2000; 46(6): 1017 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Singh, K. K. Zscheck, and B. E. Murray Efficacy of Telithromycin (HMR 3647) against Enterococci in a Mouse Peritonitis Model Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3434 - 3437. [Abstract] [Full Text]
|
|
|
|
|
|
C. Edlund, G. Alvan, L. Barkholt, F. Vacheron, and C. E. Nord Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora J. Antimicrob. Chemother., November 1, 2000; 46(5): 741 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okamoto, S. Miyazaki, K. Tateda, Y. Ishii, and K. Yamaguchi Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against Gram-positive clinical isolates in Japan J. Antimicrob. Chemother., November 1, 2000; 46(5): 797 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mikamo, Y. X. Hua, Y. Sato, Y. Hayasaki, and T. Tamaya In vitro antibacterial activities of telithromycin, a new ketolide, against bacteria causing infections in obstetric and gynaecological patients J. Antimicrob. Chemother., August 1, 2000; 46(2): 332 - 334. [Full Text] [PDF]
|
|
|
|
|
|
S. Strigl, P. M. Roblin, T. Reznik, and M. R. Hammerschlag In Vitro Activity of ABT 773, a New Ketolide Antibiotic, against Chlamydia pneumoniae Antimicrob. Agents Chemother., April 1, 2000; 44(4): 1112 - 1113. [Abstract] [Full Text]
|
|
|
|
|
|
E. J. C. Goldstein, D. M. Citron, C. V. Merriam, Y. Warren, and K. Tyrrell Activities of Telithromycin (HMR 3647, RU 66647) Compared to Those of Erythromycin, Azithromycin, Clarithromycin, Roxithromycin, and Other Antimicrobial Agents against Unusual Anaerobes Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2801 - 2805. [Abstract] [Full Text]
|
|